Targets › GHSR
1 program from 1 company in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.
G protein-coupled receptor specific to ghrelin, an appetite-regulating peptide hormone commonly found in stomach. Upon activation, stimulates appetite and promotes growth hormone secretion. (UniProt, Q92847)
Open in Phaseline: the race on GHSR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| M.D. Anderson Cancer Center | Anamorelin Hydrochloride Ghrelin receptor agonist | GHSR | Phase 2 | Anorexia; Advanced Malignant Solid Neoplasm | Dec 2026 |
Anorexia (1) Advanced Malignant Solid Neoplasm (1)
small molecule (1)
M.D. Anderson Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.